It is important to clarify, based on legal, scientific and bioethical principles, that the regulations adopted by the Federal Council of Medicine (Conselho Federal de Medicina) of Brazil as CFM Resolution no. 2,427/2025 do not represent a rollback in the rights of transgender individuals1. Instead, they constitute the legitimate exercise of an institutional duty: to ensure the safety, efficacy and scientific integrity of medical practices in Brazil, particularly those with a high biological impact on vulnerable populations, such as children and adolescents.
The main rationale for CFM Resolution no. 2,427/2025 is the low quality of current scientific evidence regarding the efficacy and safety of puberty blockers and cross-sex hormone therapy in adolescents with gender dysphoria. Recent independent systematic reviews, including the Cass Review2,3indicate that the certainty of evidence is very low across all clinical outcomes evaluated (such as the impacts on gender dysphoria and mental and psychosocial health).
